Home Based Daratumumab Administration for Patients with Multiple ...

FDA approves daratumumab and hyaluronidase-fihj with bortezomib ...

On July 30, 2024, the Food and Drug Administration approved daratumumab and ... patients with newly diagnosed multiple myeloma who.

Subcutaneous Daratumumab Offers Convenience for Patients With ...

Nearly 5 years after its approval for patients with multiple myeloma, daratumumab is now available in a formulation that can be administered ...

ASCO 2023: Multiple Myeloma - American Journal of Managed Care

The trial (NCT05511428) will study home-based subcutaneous daratumumab and hyaluronidase-fihj, sold as Darzalex Faspro, for patients with MM.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple ...

Cost-Minimization Analysis for Subcutaneous Daratumumab in the ...

The model included 2 scenarios: the current scenario in which 100% of patients with NDMM are treated with dara-IV infusion and a future scenario ...

Understanding Darzalex Faspro as a Subcutaneous Injection

Darzalex Faspro is a groundbreaking drug for the treatment of multiple myeloma, helping improve the quality of life for patients and their families.

Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal ...

Background. Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an ...

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone ...

Patients who received daratumumab plus VRd (D-VRd) had an estimated four-year PFS rate of 84.3% compared with 67.7% among those receiving VRd ...

Phase II trial of daratumumab with DCEP in relapsed/refractory ...

For patients undergoing ASCT, DARA maintenance had to be administered within 12 weeks of ASCT. During the maintenance phase, daratumumab was ...

Daratumumab and hyaluronidase-fihj (subcutaneous route)

Daratumumab and hyaluronidase-fihj combination injection is also used alone to treat multiple myeloma in patients who have received at least 3 ...

FDA Approves Daratumumab Plus VRd for Newly Diagnosed ...

Approval was based on results of the PHASE 3 PERSEUS, open-label, randomized, active-controlled trial that compared the two regimens. Enrollment ...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

DARZALEX® is the first CD38-directed antibody approved to treat multiple myeloma. ... DARZALEX®-based regimens have been used in the treatment of ...

DARZALEX - Management of Infusion-Related Reactions

IRRs occurred in 38% of patients in the DARZALEX 16 mg/kg group and 44% of patients in the DARZALEX 8 mg/kg group and were mostly grade 1/2. Grade 3 IRRs ...

A New Multiple Myeloma Indication for Daratumumab and ...

The US Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), plus bortezomib, lenalidomide, and dexamethasone.

Subcutaneous daratumumab plus standard treatment regimens in ...

Daratumumab 16 mg/kg is approved for intravenous (IV) infusion in combination with standard-of-care regimens for patients with newly diagnosed ...

Stem Cell Mobilization for Multiple Myeloma Patients Receiving ...

The addition of daratumumab to the RVd induction regimen did not lead to any clinically significant differences in stem cell yield or number of ...

Best Practice for the Administration of Daratumumab in Multiple ...

A trained health professional must deliver all daratumumab infusions. Based on experience from clinical trials, the median duration of the first infusion is 7 h ...

Daratumumab | Cancer Research UK

This means that you have the drug and then a rest to allow your body to recover. Daratumumab is given weekly to start with and then less often as time goes on.

Help Your Patients Start and Stay on DARZALEX FASPRO

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: In combination with bortezomib ...

Three-year Follow-up of CASTOR

Eligible patients had received ≥ 1 line of treatment and were administered bortezomib (1.3 mg/m2) and dexamethasone (20 mg) for 8 cycles with or ...